abobotulinumtoxinA

March 16, 2018March 16, 2018

Dysport Therapeutic Approved by Health Canada for Lower Limb Spasticity Treatment in Adults

News

AbobotulinumtoxinA, marketed as Dysport Therapeutic by Ipsen Biopharmaceuticals Canada, was approved by Health Canada for the treatment of lower limb focal spasticity in adults. Focal spasticity is a medical disorder ... Read more

June 19, 2017June 19, 2017

FDA Expands Dysport’s Approval for Treatment of Lower Limb Spasticity in Adults

News

The U.S. Food and Drug Administration (FDA) has expanded approval of Dysport (abobotulinumtoxinA) for treatment of spasticity in adults, a condition that affects many people in the United States, ... Read more

December 8, 2014December 12, 2014

Ipsen Biopharmaceuticals Announces FDA To Review sBLA For Dysport® As Treatment For Upper Limb Spasticity

Multiple Sclerosis News, News

Ipsen Biopharmaceuticals, Inc announced that the United States Food and Drug Administration (FDA) has agreed to review the supplemental Biologics License Application (sBLA) for Dysport® (abobotulinumtoxinA) to treat upper limb spasticity, a condition that ... Read more

Pin It on Pinterest